首页> 美国卫生研究院文献>Clinical Kidney Journal >The unaccomplished mission of reducing mortality in patients on kidney replacement therapy
【2h】

The unaccomplished mission of reducing mortality in patients on kidney replacement therapy

机译:降低肾脏替代疗法患者死亡率的未审议任务

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Six years ago, a comprehensive review by the EURECA-m working group of the ERA-EDTA thoroughly addressed the drivers of mortality in patients with end-stage kidney disease. Not unexpectedly, the key global driver of early death in these patients was the lack of access to kidney replacement therapy. However, and contrary to the expectations of non-nephrologists, mortality was still high when kidney replacement therapy was provided. This was due to excess cardiovascular and non-cardiovascular mortality, and the need to further characterize correctable risk factors and eventually test the impact of correcting them was emphasized. In this issue of ckj, seven reports address risk factors for death in non-dialysis chronic kidney disease (CKD), dialysis and kidney transplant patients. They characterize irreversible (e.g. sex; age; genetic variants of the KL gene encoding the anti-ageing protein Klotho) and reversible (obesity; mineral and bone disorder parameters; anti-depressant drugs, especially those that increase the QT; amputation; public health investments) factors associated with mortality of CKD patients on or off kidney replacement therapy.
机译:六年前,Eureca-M eRA-EDTA工作组全面审查彻底解决了患有终末期肾病患者的死亡率。不会出乎意料地,这些患者早期死亡的关键全球驾驶员缺乏肾脏替代疗法。然而,与非肾病学家对非肾病学家的期望相反,当提供肾脏替代疗法时,死亡率仍然很高。这是由于心血管和非心血管死亡率过剩,并且需要进一步表征可矫正危险因素,并最终测试纠正它们的影响。在这个问题的CKJ中,七个报告了非透析慢性肾病(CKD),透析和肾移植患者死亡的危险因素。它们表征不可逆转(例如性别;年龄;编码抗衰老蛋白Klotho的KL基因的遗传变异)和可逆的(肥胖;矿物质和骨骼紊乱参数;抗抑郁药,尤其是那些增加Qt的人;截肢;公共卫生投资)与CKD患者死亡率相关的因素肾置置疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号